University of California, San Diego
San Diego, California, 92093, United States
NCT Number: NCT02505594
Obstructive sleep apnea (OSA) is a common disorder with major cardiovascular sequelae. A recent study confirmed that OSA is associated with impaired exercise capacity and increasing OSA severity predicts worsening exercise capacity, which is a marker of potential increased cardiovascular risk. However, potential mechanisms of decreased exercise capacity caused by OSA remain unclear. Several pathophysiologic mechanisms of OSA have been proposed and investigators hypothesize that endothelial dysfunction leading to exercise-induced right ventricular dysfunction and associated pulmonary hypertension is the potential mechanism for impaired exercise capacity in OSA.
Looking for future studies?
Notify Me30 year–65 year
All sexes
Observational
San Diego, California, 92093, United States
Obstructive sleep apnea (OSA) is a common disorder with major cardiovascular sequelae, including increased systemic hypertension and strokes. OSA is highly prevalent among patients with cardiovascular disease (CVD), but OSA remains under-diagnosed, thus under-treated. Furthermore, a recent study confirmed that OSA is associated with impaired exercise capacity and increasing OSA severity predicts worsening exercise capacity, which is a marker of potential increased cardiovascular risk. However, potential mechanisms of decreased exercise capacity caused by OSA remain unclear.
Several pathophysiologic mechanisms of OSA have been proposed to explain this observation. Endothelial dysfunction is one mechanism that may result from OSA-related intermittent hypoxemia, heightened sympathetic activation, and increased blood pressure. Endothelial dysfunction is characterized by alteration of normal endothelial physiology consisting of a reduction in the bioavailability of vasodilators such as nitric oxide leading to impaired endothelium-depended vasodilation. Endothelial dysfunction has been consistently associated with an increased incidence of CVD. Recent evidence also suggests a correlation between endothelial function and exercise capacity.
In addition, endothelial dysfunction of pulmonary vasculature play an integral role in the pathogenesis of pulmonary hypertension (PH), which is defined by a mean pulmonary artery pressure exceeding 25 mm Hg. PH is associated with increased mortality and multiple morbidities including impaired exercise capacity. OSA has been formally recognized as a cause of PH by the World Health Organization (WHO) and the estimated prevalence of PH in patients with OSA is 17%. Repetitive nocturnal hypoxemia, increased sympathetic tone, and diminished endothelial dependent vaso-reactivity contribute to pulmonary artery hypoxic vasoconstriction, subsequently leading to pulmonary vasculature remodeling and PH. Recently, PH induced by exercise was described as part of the PH spectrum and may represent early, mild, PH that is still clinically relevant in many patients. To detect early PH in OSA patients may signify the importance of treatment and compliance for newly diagnosed OSA patients.
In summary, our hypothesis is that OSA patients may have endothelial dysfunction that leads to impaired exercise capacity via exercise-induced pulmonary hypertension. If our hypothesis is correct, non-invasive measurements of endothelial function could be used clinically to risk stratify patients or follow response to treatment.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
EndoPAT is a non-invasive measurement of endothelial function, using peripheral arterial tonometry. Exercise tolerance is measured by Cardiopulmonary exercise testing (CPET). Effects of OSA on exercise tolerance and endothelial function will be evaluated.
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Time frame: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
University of California, San Diego
Other
Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02278094
Apnea, Behavior
Tainan, Taiwan
View Trial DetailsNCT06087900
Apnea, Behavior
Pathum Wan, Bangkok, Thailand
View Trial DetailsNCT03946228
Apnea, Behavior
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT02502942
Apnea, Behavior
San Diego, California, United States
View Trial Details